BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Bayer and NextRNA Therapeutics Forge Strategic Partnership to Develop Small Molecule Therapies Targeting Long Non-Coding RNAs (lncRNAs) in Oncology

NextEdge Admin

29 Aug 2024

1 min 55 sec

NextRNA Therapeutics,oncology,partnership

Bayer and NextRNA Therapeutics have entered a collaboration and license agreement to develop small molecule therapeutics targeting long non-coding RNAs (lncRNAs) in oncology. This partnership aims to disrupt lncRNA-RNA-binding protein (RBP) interactions, opening a new avenue for cancer treatment. lncRNAs are key players in driving pathological processes across various diseases, and targeting them represents a novel therapeutic approach.

The collaboration focuses on two oncology programs addressing high unmet needs. The first program involves a lncRNA-targeting small molecule currently in early preclinical development at NextRNA. For the second program, NextRNA will advance lncRNA targets identified by its platform, with Bayer having the option to select one target for joint development.

Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division, highlighted the partnership’s potential to transform oncology pipelines by leveraging NextRNA’s expertise. Dominique Verhelle, PhD, MBA, Co-Founder and CEO of NextRNA, emphasized the recognition of lncRNAs as an exciting target class and expressed enthusiasm for working with Bayer.

NextRNA will receive up to $547 million in payments, including upfront and milestone payments, research funding, and royalties on net sales. This partnership marks a significant step in developing first-in-class cancer therapies.